SAB Corporate Presentation August 31, 2026 EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, demonstrated anticipated PD profiles and early efficacy signals in T1D patients with residual C-peptide September 30, 2026 EASD 2026 - SAB-142: Setting a New Standard for Beta-Cell Preservation September 30, 2026 EASD 2026 - Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with type 1 diabetes > 100 days post diagnosis September 30, 2026 EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, can be safely readministered, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers September 30, 2026 FOCiS 2026 - Positive Clinical Translation of a Juvenile NHP Study for Evaluating SAB-142, a Multi-Specific T-Cell Targeting T1D Therapy, in Humans June 10, 2026 ADA 2026 - Pharmacokinetics, Immunogenicity, and Pharmacodynamics Following Repeat Dosing of SAB-142, a Fully Human Multi-Specific Anti-Thymocyte Globulin for New Onset T1D June 5, 2026 IDS 2026 - Save All Beta Cells: Sustained Autoimmune Balance with SAB-142 Induction and Maintenance Dosing April 22, 2026 ATTD-2026 - Breaking the Depletion Paradigm: Immunomodulation Without Sustained Lymphodepletion with SAB-142, a Fully Human, Multi-Specific Anti-Thymocyte Globulin for T1D March 14, 2026 ATTD-2026 - Decoding the Binding Landscape for Multi-Specific T1D Biologics: Targeted Binding of Rabbit vs Human Anti-Thymocyte Globulin, SAB-142 March 12, 2026 ATTD-2026 - Charting the Safety Landscape of Multi-Specific Modalities: Safety Profile of Multi-Specific Anti-Thymocyte Globulin SAB-142 March 12, 2026
EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, demonstrated anticipated PD profiles and early efficacy signals in T1D patients with residual C-peptide September 30, 2026
EASD 2026 - Mechanism of action of SAB-142 and responsive C-peptide signal in adult patients with type 1 diabetes > 100 days post diagnosis September 30, 2026
EASD 2026 - SAB-142, a fully human anti-thymocyte globulin, can be safely readministered, is not immunogenic, and has predictable PK/PD profiles in healthy volunteers September 30, 2026
FOCiS 2026 - Positive Clinical Translation of a Juvenile NHP Study for Evaluating SAB-142, a Multi-Specific T-Cell Targeting T1D Therapy, in Humans June 10, 2026
ADA 2026 - Pharmacokinetics, Immunogenicity, and Pharmacodynamics Following Repeat Dosing of SAB-142, a Fully Human Multi-Specific Anti-Thymocyte Globulin for New Onset T1D June 5, 2026
IDS 2026 - Save All Beta Cells: Sustained Autoimmune Balance with SAB-142 Induction and Maintenance Dosing April 22, 2026
ATTD-2026 - Breaking the Depletion Paradigm: Immunomodulation Without Sustained Lymphodepletion with SAB-142, a Fully Human, Multi-Specific Anti-Thymocyte Globulin for T1D March 14, 2026
ATTD-2026 - Decoding the Binding Landscape for Multi-Specific T1D Biologics: Targeted Binding of Rabbit vs Human Anti-Thymocyte Globulin, SAB-142 March 12, 2026
ATTD-2026 - Charting the Safety Landscape of Multi-Specific Modalities: Safety Profile of Multi-Specific Anti-Thymocyte Globulin SAB-142 March 12, 2026
